As the world’s first and only highly selective JAK1 inhibitor, golidocitinib demonstrates significant efficacy in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) with a lower risk of off-target adverse reactions.
Authentic
Guarantee
Fast Delivery
Privacy Golidocitinib capsules are available for postal delivery. We will provide compliant packaging and professional distribution services, and arrange the ···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 81
Each box is priced at approximately 2,215 US dollars, containing 30 capsules of the standard specification with a dosage of 0.15 g per capsule.【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 71
Common adverse reactions of Golidocitinib include neutropenia, anemia, infections and the like. Regular monitoring of blood routine and liver function···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 71
Golidocitinib is an oral inhibitor of the JAK/STAT signaling pathway, primarily indicated for the treatment of hematologic malignancies such as relaps···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 76
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



